메뉴 건너뛰기




Volumn 12, Issue 6, 2012, Pages 775-793

The cost offsets and cost-effectiveness associated with pegylated drugs: A review of the literature

Author keywords

cost; cost offset; cost effectiveness; economic; pegylation pegylated; polyethylene glycol

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ASPARAGINASE; ASPARAGINASE MACROGOL; CAMPTOTHECIN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DOXORUBICIN; MACROGOL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGAMOTECAN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

EID: 84871487587     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.65     Document Type: Review
Times cited : (22)

References (47)
  • 1
    • 0017701219 scopus 로고
    • Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol
    • Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252(11), 3578-3581 (1977
    • (1977) J. Biol. Chem , vol.252 , Issue.11 , pp. 3578-3581
    • Abuchowski, A.1    Van Es, T.2    Palczuk, N.C.3    Davis, F.F.4
  • 2
    • 64749101544 scopus 로고    scopus 로고
    • PEG-modified biopharmaceuticals
    • Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin. Drug Deliv. 6(1), 1-16 (2009
    • (2009) Expert Opin. Drug Deliv , vol.6 , Issue.1 , pp. 1-16
    • Bailon, P.1    Won, C.Y.2
  • 3
    • 0033928514 scopus 로고    scopus 로고
    • Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs
    • Reddy KR. Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs. Ann. Pharmacother. 34(7-8), 915-923 (2000
    • (2000) Ann. Pharmacother , vol.34 , Issue.7-8 , pp. 915-923
    • Reddy, K.R.1
  • 4
    • 0000017353 scopus 로고    scopus 로고
    • Phase II trial of branched PEG (40 kDa interferon α-2a for patients with advanced renal cell carcinoma (RCC)
    • Motzer R, Thompson J, Gurney H et al. Phase II trial of branched PEG (40 kDa interferon α-2a for patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 20, 180a (2001
    • (2001) Proc. Am. Soc. Clin. Oncol , vol.20 , pp. 180
    • Motzer, R.1    Thompson, J.2    Gurney, H.3
  • 5
    • 0036087485 scopus 로고    scopus 로고
    • Novel effects with polyethylene glycol modified pharmaceuticals
    • Blackwell S.
    • Yowell SL, Blackwell S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat. Rev. 28(Suppl. A), 3-6 (2002
    • (2002) Cancer Treat. Rev , vol.28 , Issue.SUPPL. A , pp. 3-6
    • Yowell, S.L.1
  • 6
    • 0036083609 scopus 로고    scopus 로고
    • Pegylation: Engineering improved pharmaceuticals for enhanced therapy
    • Molineux G. Pegylation: Engineering improved pharmaceuticals for enhanced therapy. Cancer Treat. Rev. 28(Suppl. A), 13-16 (2002
    • (2002) Cancer Treat. Rev , vol.28 , Issue.SUPPL. A , pp. 13-16
    • Molineux, G.1
  • 8
    • 33750850799 scopus 로고    scopus 로고
    • Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil
    • Vanni T, Fonseca BA, Polanczyk CA. Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil. HIV Clin. Trials 7(4), 194-202 (2006
    • (2006) HIV Clin. Trials , vol.7 , Issue.4 , pp. 194-202
    • Vanni, T.1    Fonseca, B.A.2    Polanczyk, C.A.3
  • 9
    • 0032529420 scopus 로고    scopus 로고
    • Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma
    • Bennett CL, Golub RM, Stinson TJ et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18(5), 460-465 (1998
    • (1998) J. Acquir. Immune Defic. Syndr. Hum. Retrovirol , vol.18 , Issue.5 , pp. 460-465
    • Bennett, C.L.1    Golub, R.M.2    Stinson, T.J.3
  • 10
    • 0033427746 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma
    • Hjortsberg C, Persson U, Lidbrink E, Bennett C. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. Acta Oncol. 38(8), 1063-1067 (1999
    • (1999) Acta Oncol , vol.38 , Issue.8 , pp. 1063-1067
    • Hjortsberg, C.1    Persson, U.2    Lidbrink, E.3    Bennett, C.4
  • 11
    • 34249791805 scopus 로고    scopus 로고
    • Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/ dexamethasone versus doxorubicin/ vincristine/ dexamethasone in patients with newly diagnosed multiple myeloma
    • Porter CA, Rifkin RM. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/ dexamethasone versus doxorubicin/ vincristine/dexamethasone in patients with newly diagnosed multiple myeloma. Clin. Lymphoma Myeloma 7(Suppl. 4), S150-S155 (2007
    • (2007) Clin. Lymphoma Myeloma , vol.7 , Issue.SUPPL. 4
    • Porter, C.A.1    Rifkin, R.M.2
  • 12
    • 70349897133 scopus 로고    scopus 로고
    • The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK
    • Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl. Health Econ. Health Policy 7(3), 193-205 (2009
    • (2009) Appl. Health Econ. Health Policy , vol.7 , Issue.3 , pp. 193-205
    • Liu, Z.1    Doan, Q.V.2    Malin, J.3    Leonard, R.4
  • 13
    • 66949127931 scopus 로고    scopus 로고
    • Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States
    • Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin. Ther. 31(5), 1092-1104 (2009
    • (2009) Clin. Ther , vol.31 , Issue.5 , pp. 1092-1104
    • Lyman, G.H.1    Lalla, A.2    Barron, R.L.3    Dubois, R.W.4
  • 14
    • 41549115442 scopus 로고    scopus 로고
    • Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy
    • Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 11(2), 172-179 (2008
    • (2008) Value Health , vol.11 , Issue.2 , pp. 172-179
    • Eldar-Lissai, A.1    Cosler, L.E.2    Culakova, E.3    Lyman, G.H.4
  • 15
    • 4444288448 scopus 로고    scopus 로고
    • Cost-effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C
    • Sullivan SD, Jensen DM, Bernstein DE et al. Cost-effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C. Am. J. Gastroenterol. 99(8), 1490-1496 (2004
    • (2004) Am. J. Gastroenterol , vol.99 , Issue.8 , pp. 1490-1496
    • Sullivan, S.D.1    Jensen, D.M.2    Bernstein, D.E.3
  • 16
    • 2142695339 scopus 로고    scopus 로고
    • A health economic model to assess the long term effects and cost-effectiveness of PEG IFN α-2a in hepatitis C virus infected patients
    • Annemans L, Warie H, Nechelput M, Peraux B. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN α-2a in hepatitis C virus infected patients. Acta Gastroenterol. Belg. 67(1), 1-8 (2004
    • (2004) Acta Gastroenterol. Belg , vol.67 , Issue.1 , pp. 1-8
    • Annemans, L.1    Warie, H.2    Nechelput, M.3    Peraux, B.4
  • 17
    • 33749670275 scopus 로고    scopus 로고
    • Adefovir dipivoxil and PEG interferon α-2a for the treatment of chronic hepatitis B: A systematic review and economic evaluation
    • iii-iv, xi-xiv
    • Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and PEG interferon α-2a for the treatment of chronic hepatitis B: A systematic review and economic evaluation. Health Technol Assess. 10(iii-iv, xi-xiv), 1-183 (2006
    • (2006) Health Technol Assess , vol.10 , pp. 1-183
    • Shepherd, J.1    Jones, J.2    Takeda, A.3    Davidson, P.4    Price, A.5
  • 18
    • 77956258983 scopus 로고    scopus 로고
    • PATRONUS Investigators Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin β versus darbepoetin α administered monthly: A randomized comparative trial
    • Carrera F, Lok CE, de Francisco A et al.; PATRONUS Investigators. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin β versus darbepoetin α administered monthly: A randomized comparative trial. Nephrol. Dial. Transplant. 25(12), 4009-4017 (2010
    • (2010) Nephrol. Dial. Transplant , vol.25 , Issue.12 , pp. 4009-4017
    • Carrera, F.1    Lok, C.E.2    De Francisco, A.3
  • 20
    • 77649126999 scopus 로고    scopus 로고
    • Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: A cost-effectiveness analysis for Germany
    • Sehouli J, Goertz A, Steinle T et al. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: A cost-effectiveness analysis for Germany]. Dtsch. Med. Wochenschr. 135(9), 385-389 (2010
    • (2010) Dtsch. Med. Wochenschr , vol.1359 , pp. 385-389
    • Sehouli, J.1    Goertz, A.2    Steinle, T.3
  • 21
    • 78651342871 scopus 로고    scopus 로고
    • Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
    • Samaras P, Blickenstorfer M, Siciliano RD et al. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Ann. Hematol. 90(1), 89-94 (2011
    • (2011) Ann. Hematol , vol.90 , Issue.1 , pp. 89-94
    • Samaras, P.1    Blickenstorfer, M.2    Siciliano, R.D.3
  • 22
    • 70350109377 scopus 로고    scopus 로고
    • Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim or chemotherapy-induced neutropenia
    • Heaney ML, Toy EL, Vekeman F et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim or chemotherapy-induced neutropenia. Cancer 115(20), 4839-4848 (2009
    • (2009) Cancer , vol.115 , Issue.20 , pp. 4839-4848
    • Heaney, M.L.1    Toy, E.L.2    Vekeman, F.3
  • 23
    • 84871490150 scopus 로고    scopus 로고
    • Cost-minimization analysis of once-percycle fixed-dose administration of PEGfilgrastim versus dail filgrastrim for the prophylaxis of chemotherapy-induced febrile neutropenia in Brazil
    • 20-23 October
    • Lago S, Nasciben V, Saggia M. Cost-minimization analysis of once-percycle fixed-dose administration of PEGfilgrastim versus dail filgrastrim for the prophylaxis of chemotherapy-induced febrile neutropenia in Brazil. Presented at: ISPOR Tenth Annual European Congress. Dublin, Ireland, 20-23 October 2007
    • (2007) Presented at: ISPOR Tenth Annual European Congress. Dublin Ireland
    • Lago, S.1    Nasciben, V.2    Saggia, M.3
  • 25
    • 84871477246 scopus 로고    scopus 로고
    • Analysis on cost difference between daily filgrastim and one per cycle pegfilgrastim for prophylaxis against chemotherapy-induced neutropenia in France and Germany. Presented at: ISPOR Sixth Annual European Congress. Barcelona
    • 9-11 November
    • Suczs T, Standaert B, Lu Z. Analysis on cost difference between daily filgrastim and one per cycle pegfilgrastim for prophylaxis against chemotherapy-induced neutropenia in France and Germany. Presented at: ISPOR Sixth Annual European Congress. Barcelona, Spain, 9-11 November 2003
    • (2003) Spain
    • Suczs, T.1    Standaert, B.2    Lu, Z.3
  • 27
    • 84871479151 scopus 로고    scopus 로고
    • Cost utility analysis of primary prophylaxis with pegfilgrastim versus filgrastim for breast cancer in the UK
    • Copenhagen Denmark 28-31 October
    • Booth P, Dubois R, Doan Q, Liu Z. Cost utility analysis of primary prophylaxis with pegfilgrastim versus filgrastim for breast cancer in the UK. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28-31 October 2006
    • (2006) Presented at: ISPOR Ninth Annual European Congress
    • Booth, P.1    Dubois, R.2    Doan, Q.3    Liu, Z.4
  • 28
    • 84871494568 scopus 로고    scopus 로고
    • Cost-effectivenss of pegfligrastim versus filgrastim after high-dose chemctherapy and autologous stem cell transplantation in patients with lymphoma nad myeloma
    • Presented at: 5-8 November 2011
    • Perrier L, Lefranc A, Quittet P et al. Cost-effectivenss of pegfligrastim versus filgrastim after high-dose chemctherapy and autologous stem cell transplantation in patients with lymphoma nad myeloma. Presented at: ISPOR Fourteenth Annual European Congress, Madrid, Spain, 5-8 November 2011
    • ISPOR Fourteenth Annual European Congress, Madrid, Spain
    • Perrier, L.1    Lefranc, A.2    Quittet, P.3
  • 29
    • 84871517054 scopus 로고    scopus 로고
    • Primary prophylaxis against febrile neutropenia with PEGfilgrastim is cost-effective compared with filgrastim in non-Hodgkin's lymphoma patients receiving chop-21 in Italy
    • Dublin Ireland 20-23 October
    • Chiroli S, Health Ciceri F, Atchison C, Malin J, Doan Q. Primary prophylaxis against febrile neutropenia with PEGfilgrastim is cost-effective compared with filgrastim in non-Hodgkin's lymphoma patients receiving chop-21 in Italy. Presented at: ISPOR Tenth Annual European Congress. Dublin, Ireland, 20-23 October 2007
    • (2007) Presented at: ISPOR Tenth Annual European Congress
    • Chiroli, S.1    Health Ciceri, F.2    Atchison, C.3    Malin, J.4    Doan, Q.5
  • 30
    • 84871499362 scopus 로고    scopus 로고
    • Cost-effectiveness of primary prophylaxis with PEGfilgrastim versus filgrastim for reducing incidence of febrile neutropenia in non-Hodgkin lymphoma and stage II breast cancer patients in Germany
    • Prague Czech Republic 6-9 November 2010
    • Taylor D, Ozer-Deniz S, Hill G, Skornicki M, Danel A, Erika K. Cost-effectiveness of primary prophylaxis with PEGfilgrastim versus filgrastim for reducing incidence of febrile neutropenia in non-Hodgkin lymphoma and stage II breast cancer patients in Germany. Presented at: ISPOR 13th Annual European Conference. Prague, Czech Republic, 6-9 November 2010
    • Presented at: ISPOR 13th Annual European Conference
    • Taylor, D.1    Ozer-Deniz, S.2    Hill, G.3    Skornicki, M.4    Danel, A.5    Erika, K.6
  • 31
    • 84871489771 scopus 로고    scopus 로고
    • Cost effectiveness of primary prophylaxis with pegfilgrastim or filgrastim in the medical treatment of breast cancer in Italy
    • Copenhagen Denmark 28-31 October
    • Chiroli S, Dubois R, Doan Q et al. Cost effectiveness of primary prophylaxis with pegfilgrastim or filgrastim in the medical treatment of breast cancer in Italy. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28-31 October 2006
    • (2006) Presented at: ISPOR Ninth Annual European Congress
    • Chiroli, S.1    Dubois, R.2    Doan, Q.3
  • 32
    • 67649126886 scopus 로고    scopus 로고
    • Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients
    • Danova M, Chiroli S, Rosti G, Doan QV. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori 95(2), 219-226 (2009
    • (2009) Tumori , vol.95 , Issue.2 , pp. 219-226
    • Danova, M.1    Chiroli, S.2    Rosti, G.3    Doan, Q.V.4
  • 33
    • 64249170087 scopus 로고    scopus 로고
    • Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States
    • Lyman G, Lalla A, Barron R, Dubois RW. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr. Med. Res. Opin. 25(2), 401-411 (2009
    • (2009) Curr. Med. Res. Opin , vol.25 , Issue.2 , pp. 401-411
    • Lyman, G.1    Lalla, A.2    Barron, R.3    Dubois, R.W.4
  • 34
    • 84871474936 scopus 로고    scopus 로고
    • Primary prophylaxis against febrile neutropenia with PEGfilgrastim is cost-effective compared with filgrastim in non-Hodgkin's lymphoma patients receiving CHOP-21 in Spain
    • Dublin Ireland 20-23 October Doxil® Package Insert. Janssen Biotech Horsham PA USA. 38 Pegasys® Package Insert. Genentech South San Francisco CA USA. Pegasys®, package insert. Genentech, South San Francisco, CA, USA. 39 PegInteron®, package insert. Merck, Whitehouse Station, NJ, USA
    • Arocho R, Atchison C, Malin J. Primary prophylaxis against febrile neutropenia with PEGfilgrastim is cost-effective compared with filgrastim in non-Hodgkin's lymphoma patients receiving CHOP-21 in Spain. Presented at: ISPOR Tenth Annual European Congress. Dublin, Ireland, 20-23 October 2007 Doxil®, package insert. Janssen Biotech, Horsham, PA, USA PegInteron® Package Insertt Merck Whitehouse Station NJ USA.
    • (2007) Presented at: ISPOR Tenth Annual European Congress
    • Arocho, R.1    Atchison, C.2    Malin, J.3
  • 35
    • 33746026313 scopus 로고    scopus 로고
    • Cost-effectiveness Of Peginterferon α-2a (40 KDa) Plus Ribavirin In Patients With HIV And Hepatitis C Virus Co-infection
    • Hornberger J, Torriani FJ, Dieterich DT et al. Cost-effectiveness of peginterferon α-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J. Clin. Virol. 36(4), 283-291 (2006
    • (2006) J. Clin. Virol , vol.36 , Issue.4 , pp. 283-291
    • Hornberger, J.1    Torriani, F.J.2    Dieterich, D.T.3
  • 36
    • 77749283196 scopus 로고    scopus 로고
    • Cost effectiveness of peginterferon α-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil
    • Fonseca MC, Araújo GT, Araújo DV. Cost effectiveness of peginterferon α-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil. Braz. J. Infect. Dis. 13(3), 191-199 (2009
    • (2009) Braz. J. Infect. Dis , vol.13 , Issue.3 , pp. 191-199
    • Fonseca, M.C.1    Araújo, G.T.2    Araújo, D.V.3
  • 37
    • 0038352047 scopus 로고    scopus 로고
    • Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population
    • Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290(2), 228-237 (2003
    • (2003) JAMA , vol.290 , Issue.2 , pp. 228-237
    • Salomon, J.A.1    Weinstein, M.C.2    Hammitt, J.K.3    Goldie, S.J.4
  • 38
    • 9944225119 scopus 로고    scopus 로고
    • PEG interferon α-2a and-2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation
    • iii-iv
    • Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. PEG interferon α-2a and-2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol. Assess. 8(iii-iv), 1-125 (2004
    • (2004) Health Technol. Assess , vol.8 , pp. 1-125
    • Shepherd, J.1    Brodin, H.2    Cave, C.3    Waugh, N.4    Price, A.5    Gabbay, J.6
  • 39
    • 84871513114 scopus 로고    scopus 로고
    • The cost-effectiveness analysis of PEGinterferon α-2a and ribavirin versus interferon α-2b and ribavirin in chronic hepatitis C in Poland. Presented at: ISPOR Sixth Annual European Congress. Barcelona
    • 9-11 November
    • Orlewska E, Juszczyk J. The cost-effectiveness analysis of PEGinterferon α-2a and ribavirin versus interferon α-2b and ribavirin in chronic hepatitis C in Poland. Presented at: ISPOR Sixth Annual European Congress. Barcelona, Spain, 9-11 November 2003
    • (2003) Spain
    • Orlewska, E.1    Juszczyk, J.2
  • 40
    • 84871499088 scopus 로고    scopus 로고
    • Cost-effectiveness of PEGinterferon α-2a (40 kd for the treatment of chronic hepatitis B in Italy
    • Copenhagen Denmark 28-31 October
    • Eandi M, Iannazzo S, Pradelli L Cost-effectiveness of PEGinterferon α-2a (40 kd for the treatment of chronic hepatitis B in Italy. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28-31 October 2006
    • (2006) Presented at: ISPOR Ninth Annual European Congress
    • Eandi, M.1    Iannazzo, S.2    Pradelli, L.3
  • 41
    • 84891685662 scopus 로고    scopus 로고
    • Health benefits of antiviral therapy for mild chronic hepatitis C: Randomised controlled trial and economic evaluation
    • UK Mild Hepatitis C Trial Investigators iii
    • Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: Randomised controlled trial and economic evaluation. Health Technol. Assess. 10(21), 1-113, iii (2006
    • (2006) Health Technol. Assess , vol.10 , Issue.21 , pp. 1-113
    • Wright, M.1    Grieve, R.2    Roberts, J.3    Main, J.4    Thomas, H.C.5
  • 42
    • 84871525641 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of PEG interferons combined with ribavirin in the treatment of hepatitis C
    • Barcelona Spain 9-11 November
    • Mar J, Antonanzas F, Velasco M et al. Cost-effectiveness analysis of PEG interferons combined with ribavirin in the treatment of hepatitis C. Presented at: ISPOR Sixth Annual European Congress. Barcelona, Spain, 9-11 November 2003
    • (2003) Presented at: ISPOR Sixth Annual European Congress
    • Mar, J.1    Antonanzas, F.2    Velasco, M.3
  • 43
    • 0036214409 scopus 로고    scopus 로고
    • A pharmacoeconomic analysis of PEGaspargase versus native Escherichia coli l-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: The Children's Cancer Group study (CCG-1962
    • Kurre HA, Ettinger AG, Veenstra DL et al. A pharmacoeconomic analysis of PEGaspargase versus native Escherichia coli l-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: The Children's Cancer Group study (CCG-1962). J. Pediatr. Hematol. Oncol. 24(3), 175-181 (2002
    • (2002) J. Pediatr. Hematol. Oncol , vol.24 , Issue.3 , pp. 175-181
    • Kurre, H.A.1    Ettinger, A.G.2    Veenstra, D.L.3
  • 44
    • 84871509104 scopus 로고    scopus 로고
    • Cost-minimization analysis: Mircera (methoxypolytheylene glycol-epoetin β) vs. Anranesp (darbepoetin α) in patients with chronic kidney disease (CKD) who are not receiving haemodialysis, in Polish etting
    • 24-27 October
    • Kawalec P, Kuzma J, Szkultecka-Debek M et al. Cost-minimization analysis: Mircera (methoxypolytheylene glycol-epoetin β) vs. Anranesp (darbepoetin α) in patients with chronic kidney disease (CKD) who are not receiving haemodialysis, in Polish etting. Presented at: ISPOR 12th Annual European Conference. Paris, France, 24-27 October 2009
    • (2009) Presented at: ISPOR 12th Annual European Conference. Paris, France
    • Kawalec, P.1    Kuzma, J.2    Szkultecka-Debek, M.3
  • 45
    • 72949096583 scopus 로고    scopus 로고
    • Good research practices for measuring drug costs in cost-effectiveness analyses: A societal perspective: The ISPOR Drug Cost Task Force report-Part I.I
    • Garrison LP Jr, Mansley EC, Abbott TA 3rd, Bresnahan BW, Hay JW, Smeeding J Good research practices for measuring drug costs in cost-effectiveness analyses: A societal perspective: The ISPOR Drug Cost Task Force report-Part II. Value Health 13(1), 8-13 (2010
    • (2010) Value Health , vol.13 , Issue.1 , pp. 8-13
    • Garrison Jr., L.P.1    Mansley, E.C.2    Abbott III, T.A.3    Bresnahan, B.W.4    Hay, J.W.5    Smeeding, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.